Pathway-Based Analysis of Genome-Wide Association Data Identified SNPs in HMMR as Biomarker for Chemotherapy- Induced Neutropenia in Breast Cancer Patients

Neutropenia secondary to chemotherapy in breast cancer patients can be life-threatening and there are no biomarkers available to predict the risk of drug-induced neutropenia in those patients. We previously performed a genome-wide association study (GWAS) for neutropenia events in women with breast cancer who were treated with 5-fluorouracil, epirubicin and cyclophosphamide and recruited to the SUCCESS-A trial. A genome-wide significant single-nucleotide polymorphism (SNP) signal in the tumor necrosis factor superfamily member 13B (TNFSF13B) gene, encoding the cytokine B-cell activating factor (BAFF), was identified in that GWAS. Taking advantage of these existing GWAS data, in the present study we utilized a pathway-based analysis approach by leveraging knowledge of the pharmacokinetics and pharmacodynamics of drugs and breast cancer pathophysiology to identify additional SNPs/genes associated with the underlying etiology of chemotherapy-induced neutropenia. We identified three SNPs in the hyaluronan mediated motility receptor (HMMR) gene that were significantly associated with neutropenia (p < 1.0E-04). Those three SNPs were trans-expression quantitative trait loci for the expression of TNFSF13B (p < 1.0E-04). The minor allele of these HMMR SNPs was associated with a decreased TNFSF13B mRNA level. Additional functional studies performed with lymphoblastoid cell lines (LCLs) demonstrated that LCLs possessing the minor allele for the HMMR SNPs were more sensitive to drug treatment. Knock-down of TNFSF13B in LCLs and HL-60 promyelocytic cells and treatment of those cells with BAFF modulated the cell sensitivity to chemotherapy treatment. These results demonstrate that HMMR SNP-dependent cytotoxicity of these chemotherapeutic agents might be related to TNFSF13B expression level. In summary, utilizing a pathway-based approach for the analysis of GWAS data, we identified additional SNPs in the HMMR gene that were associated with neutropenia and also were correlated with TNFSF13B expression.

[1]  Jiang F Zhong,et al.  Single-cell transcriptomes reveal the mechanism for a breast cancer prognostic gene panel , 2018, Oncotarget.

[2]  A. Munshi,et al.  Association of CYP2C19*2 and ALDH1A1*1/*2 variants with disease outcome in breast cancer patients: results of a global screening array , 2018, European Journal of Clinical Pharmacology.

[3]  Krishna R. Kalari,et al.  Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes , 2017, npj Breast Cancer.

[4]  Liewei Wang,et al.  Regulation of Serine-Threonine Kinase Akt Activation by NAD+-Dependent Deacetylase SIRT7. , 2017, Cell reports.

[5]  Shuji Hashimoto,et al.  Pharmacogenomic Study of Clozapine-Induced Agranulocytosis/Granulocytopenia in a Japanese Population , 2016, Biological Psychiatry.

[6]  R. Schilsky,et al.  Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Daly,et al.  Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia , 2016, Molecular Psychiatry.

[8]  C. Caldas,et al.  The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control Study , 2016, PloS one.

[9]  D. Cohen,et al.  Genetic risk factors for clozapine-induced neutropenia and agranulocytosis in a Dutch psychiatric population , 2016, The Pharmacogenomics Journal.

[10]  M. Beckmann,et al.  The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial , 2015, Breast Cancer Research.

[11]  P. Niravath,et al.  The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis , 2015, Breast Cancer Research and Treatment.

[12]  Thomas J. Smith,et al.  Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Markwald,et al.  Interactions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and Cancer , 2015, Front. Immunol..

[14]  G. Lyman,et al.  Assessing patients’ risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk? , 2015, Cancer medicine.

[15]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[16]  Liewei Wang,et al.  Abstract 2782: The effect of ERRFI1 as a novel AKT regulator on cell proliferation and response to therapy is cell context dependent , 2014 .

[17]  Erin E. Carlson,et al.  Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics. , 2014, Molecular endocrinology.

[18]  M. Daly,et al.  Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles , 2014, Nature Communications.

[19]  Tanja Fehm,et al.  Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients , 2014, Journal of the National Cancer Institute.

[20]  B. Lederer,et al.  Management of Breast Cancer Patients with Chemotherapy-Induced Neutropenia or Febrile Neutropenia , 2014, Breast Care.

[21]  B. Fridley,et al.  Thiopurine pharmacogenomics: association of SNPs with clinical response and functional validation of candidate genes. , 2014, Pharmacogenomics.

[22]  Krishna R. Kalari,et al.  Discovery of genetic biomarkers contributing to variation in drug response of cytidine analogues using human lymphoblastoid cell lines , 2014, BMC Genomics.

[23]  Dan M Roden,et al.  Genome-wide association studies in pharmacogenomics: successes and lessons , 2013, Pharmacogenetics and genomics.

[24]  L. Willen,et al.  No Evidence That Soluble TACI Induces Signalling via Membrane-Expressed BAFF and APRIL in Myeloid Cells , 2013, PloS one.

[25]  J. Woo,et al.  Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients , 2013, Journal of Cancer Research and Clinical Oncology.

[26]  J. Marchini,et al.  Fast and accurate genotype imputation in genome-wide association studies through pre-phasing , 2012, Nature Genetics.

[27]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[28]  Jason H. Moore,et al.  Pathway analysis of genomic data: concepts, methods, and prospects for future development. , 2012, Trends in genetics : TIG.

[29]  M. Stojak,et al.  Mafosfamide as a new anticancer agent: preclinical investigations and clinical trials. , 2012, Anticancer research.

[30]  M. Dolan,et al.  Using Germline Genomics to Individualize Pediatric Cancer Treatments , 2012, Clinical Cancer Research.

[31]  Y. Tamaki,et al.  MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide , 2012, Breast Cancer Research and Treatment.

[32]  A. Malhotra,et al.  Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. , 2011, The Journal of clinical psychiatry.

[33]  Richard M Weinshilboum,et al.  Genomics and drug response. , 2011, The New England journal of medicine.

[34]  G. Hortobagyi,et al.  Gene Polymorphisms in Cyclophosphamide Metabolism Pathway, Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer , 2010, Clinical Cancer Research.

[35]  H. Hakonarson,et al.  Analysing biological pathways in genome-wide association studies , 2010, Nature Reviews Genetics.

[36]  Krishna R. Kalari,et al.  Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines. , 2010, Genome research.

[37]  Yusuke Nakamura,et al.  Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Mark T. W. Ebbert,et al.  A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer , 2010, Clinical Cancer Research.

[39]  Peilin Jia,et al.  Common variants conferring risk of schizophrenia: A pathway analysis of GWAS data , 2010, Schizophrenia Research.

[40]  Judy H. Cho,et al.  Pathway analysis comparison using Crohn's disease genome wide association studies , 2010, BMC Medical Genomics.

[41]  Seung-Hee Lee,et al.  Reverse signaling through BAFF differentially regulates the expression of inflammatory mediators and cytoskeletal movements in THP‐1 cells , 2010, Immunology and cell biology.

[42]  Yusuke Nakamura,et al.  Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients , 2009, Journal of Human Genetics.

[43]  Krishna R. Kalari,et al.  FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. , 2009, Cancer cell.

[44]  Manuel A. R. Ferreira,et al.  Gene ontology analysis of GWA study data sets provides insights into the biology of bipolar disorder. , 2009, American journal of human genetics.

[45]  P. Matthews,et al.  Pathway and network-based analysis of genome-wide association studies in multiple sclerosis , 2009, Human molecular genetics.

[46]  N. Schork,et al.  Pathway analysis of seven common diseases assessed by genome-wide association. , 2008, Genomics.

[47]  Krishna R. Kalari,et al.  Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. , 2008, Cancer research.

[48]  X. Mariette,et al.  Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery. , 2007, Haematologica.

[49]  D. Jelinek,et al.  A role for BLyS in the activation of innate immune cells. , 2006, Blood.

[50]  N. Kearney,et al.  EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. , 2006, European journal of cancer.

[51]  S. Ansell,et al.  Targeting B-lymphocyte stimulator/B-cell activating factor and a proliferation-inducing ligand in hematologic malignancies. , 2006, Clinical lymphoma & myeloma.

[52]  D. Reich,et al.  Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.

[53]  B. Wiens,et al.  First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  R. Weinshilboum,et al.  Pharmacogenomics: Bench to bedside. , 2005, Discovery medicine.

[55]  Rafael A. Irizarry,et al.  A Model-Based Background Adjustment for Oligonucleotide Expression Arrays , 2004 .

[56]  C. Ulrich,et al.  Cancer pharmacogenetics: polymorphisms, pathways and beyond , 2003, Nature Reviews Cancer.

[57]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[58]  M. Piccart,et al.  Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  F. Mackay,et al.  BAFF: A fundamental survival factor for B cells , 2002, Nature Reviews Immunology.

[60]  F. Holmes,et al.  Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[61]  G. Budd,et al.  Delivering adjuvant chemotherapy to women with early‐stage breast carcinoma , 2001, Cancer.

[62]  H. Freeman,et al.  Neutropenia and Agranulocytosis in Patients Receiving Clozapine in the UK and Ireland , 1996, British Journal of Psychiatry.

[63]  J. Lieberman,et al.  Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. , 1993, The New England journal of medicine.

[64]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[65]  H. Heimpel,et al.  Clozapine-induced agranulocytosis , 2004, Blut.

[66]  T. Wager.  Correspondence should be addressed to: , 2000 .

[67]  Hiroyuki Ogata,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..